Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS.
Ramachandra N, Vegivinti CTR, Sahu S, Sanawar R, Rivera-Peña B, Aminov S, Fromowitz A, Zhang J, Aodengtuya F, Pradhan K, Zhao R, Schwartz L, Alluri S, Thiruvananthapuram V, Rabinovich E, Ajibade O, Gordon-Mitchell S, Shastri A, Deken M, Yingling JM, Sawyer S, Lahn M, Verma A. Ramachandra N, et al. Among authors: deken m. Leuk Lymphoma. 2024 Dec 27:1-10. doi: 10.1080/10428194.2024.2444479. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39727008
Characterization and translational development of IOA-289, a novel autotaxin inhibitor for the treatment of solid tumors.
Deken MA, Niewola-Staszkowska K, Peyruchaud O, Mikulčić N, Antolić M, Shah P, Cheasty A, Tagliavini A, Nizzardo A, Pergher M, Ziviani L, Milleri S, Pickering C, Lahn M, van der Veen L, Di Conza G, Johnson Z. Deken MA, et al. Immunooncol Technol. 2023 Apr 8;18:100384. doi: 10.1016/j.iotech.2023.100384. eCollection 2023 Jun. Immunooncol Technol. 2023. PMID: 37234285 Free PMC article.
Pancreatic CAF-derived Autotaxin (ATX) drives autocrine CTGF expression to modulate pro-tumorigenic signaling.
Volat F, Medhi R, Maggs LZ, Deken MA, Price A, Andrews L, Clark J, Taylor D, Carruthers A, Taylor-Smith E, Pacheco N, Rudge SA, Fraser A, Lopez-Clavijo AF, Sousa BC, Johnson Z, Di Conza G, van der Veen L, Shah P, Sandig H, Sharpe HJ, Farrow S. Volat F, et al. Among authors: deken ma. Mol Cancer Ther. 2024 Nov 21. doi: 10.1158/1535-7163.MCT-23-0522. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39570650
89Zr-Trastuzumab PET/CT Imaging of HER2-Positive Breast Cancer for Predicting Pathological Complete Response after Neoadjuvant Systemic Therapy: A Feasibility Study.
Linders DGJ, Deken MM, van Dam MA, Wasser MNJM, Voormolen EMC, Kroep JR, van Dongen GAMS, Vugts D, Oosterkamp HM, Straver ME, van de Velde CJH, Cohen D, Dibbets-Schneider P, van Velden FHP, Pereira Arias-Bouda LM, Vahrmeijer AL, Liefers GJ, de Geus-Oei LF, Hilling DE. Linders DGJ, et al. Among authors: deken mm. Cancers (Basel). 2023 Oct 13;15(20):4980. doi: 10.3390/cancers15204980. Cancers (Basel). 2023. PMID: 37894346 Free PMC article.
CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy.
Linders D, Deken M, van der Valk M, Tummers W, Bhairosingh S, Schaap D, van Lijnschoten G, Zonoobi E, Kuppen P, van de Velde C, Vahrmeijer A, Farina Sarasqueta A, Sier C, Hilling D. Linders D, et al. Among authors: deken m. Diagnostics (Basel). 2021 Mar 14;11(3):516. doi: 10.3390/diagnostics11030516. Diagnostics (Basel). 2021. PMID: 33799475 Free PMC article.
31 results